<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405820</url>
  </required_header>
  <id_info>
    <org_study_id>101MS206</org_study_id>
    <secondary_id>2010-024000-10</secondary_id>
    <nct_id>NCT01405820</nct_id>
  </id_info>
  <brief_title>Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)</brief_title>
  <acronym>REFINE</acronym>
  <official_title>A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to explore the effects of multiple regimens of
      natalizumab on disease activity and safety in participants with relapsing-remitting Multiple
      Sclerosis (RRMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a a dose and frequency (but not route of administration) blinded, prospective,
      randomized, dose-ranging study in patients with RRMS who have received natalizumab for at
      least 12 months according to the local prescribing guidelines. The study will explore dosing
      of natalizumab by subcutaneous and intravenous routes. Participants will be randomly assigned
      to 1 of 6 dosing regimens, blinded to natalizumab dose, but not route, for 60 weeks of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Number of Combined Unique Active Lesions</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Cumulative number of combined unique active lesions (sum of the number of new gadolinium (Gd)-enhancing lesions and new or newly enlarging T2 hyperintense lesions not associated with Gd-enhancement on T1 weighted scans) based on brain magnetic resonance imaging (MRI) scans Up to Week 60.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Natalizumab 300 mg Intravenous (IV) Every 4 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natalizumab 300 mg IV Every 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natalizumab 300 mg SC Every 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natalizumab 150 mg IV Every 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natalizumab 150 mg SC Every 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natalizumab IV</intervention_name>
    <description>natalizumab for IV Infusion</description>
    <arm_group_label>Natalizumab 300 mg Intravenous (IV) Every 4 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 300 mg IV Every 12 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 300 mg SC Every 12 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 150 mg IV Every 12 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 150 mg SC Every 12 Weeks</arm_group_label>
    <other_name>Tysabri</other_name>
    <other_name>BG00002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natalizumab SC</intervention_name>
    <description>natalizumab for Subcutaneous Injection</description>
    <arm_group_label>Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 300 mg SC Every 12 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 150 mg SC Every 12 Weeks</arm_group_label>
    <other_name>Tysabri</other_name>
    <other_name>BG00002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Placebo</intervention_name>
    <description>Intravenous placebo to natalizumab</description>
    <arm_group_label>Natalizumab 300 mg IV Every 12 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 150 mg IV Every 12 Weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC Placebo</intervention_name>
    <description>Subcutaneous placebo to natalizumab</description>
    <arm_group_label>Natalizumab 300 mg SC Every 12 Weeks</arm_group_label>
    <arm_group_label>Natalizumab 150 mg SC Every 12 Weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Ability to provide written informed consent

          -  Subjects of childbearing potential must practice effective contraception during the
             study

          -  A documented diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS)

          -  Free of MS relapse for 12 months prior to randomization

          -  Treatment with natalizumab for a minimum of 12 months immediately prior to
             randomization.

          -  In the 12 months prior to commencing natalizumab, subject must have experienced a
             minimal level of disease activity as defined by 2 or more documented clinical relapses
             OR 1 relapse and documented MRI activity, defined by the presence of at least 1 Gd
             enhancing lesion on MRI, unrelated to the relapse.

        Key Exclusion Criteria:

          -  Known history of Human Immunodeficiency Virus (HIV), hepatitis C and/or hepatitis B
             virus

          -  Positive for anti-natalizumab antibodies at screening

          -  MRI positive for Gd-enhancing lesions at study entry

          -  Subjects for whom MRI is contraindicated

          -  History of any clinically significant cardiac, endocrinologic, hematologic, hepatic,
             immunologic, metabolic (including diabetes), urologic, pulmonary, neurologic (except
             for RRMS), dermatologic, psychiatric, renal, or other major disease

          -  History of malignant disease, including solid tumors and hematologic malignancies
             (with the exception of cured basal cell and squamous cell carcinomas of the skin)

          -  History of transplantation or any anti-rejection therapy

          -  History of severe allergic or anaphylactic reactions or known hypersensitivity to any
             drug

          -  A clinically significant infectious illness within 30 days prior to screening or
             progressive multifocal leukoencephalopathy (PML) or other opportunistic infections at
             any time

          -  Signs or symptoms suggestive of any serious infection, based on medical history,
             physical examination or laboratory testing

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overpelt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Besançon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bron cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 01</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Andernach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Emmendingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neuburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wermsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cefalù</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gallarate</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>L'Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montichiari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pozzilli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <results_first_submitted>June 29, 2015</results_first_submitted>
  <results_first_submitted_qc>June 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2015</results_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four of the 6 arms in the Randomized Treatment Period (the ‘every 12 weeks’ arms) were closed prematurely. Participants who completed randomized treatment, met rescue criteria, or were impacted by arm closure (and met rescue criteria) were eligible to enroll in the open-label treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Natalizumab 300 mg Intravenous (IV) Every 4 Weeks</title>
          <description>Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="P2">
          <title>Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks</title>
          <description>Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="P3">
          <title>Natalizumab 300 mg IV Every 12 Weeks</title>
          <description>Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="P4">
          <title>Natalizumab 300 mg SC Every 12 Weeks</title>
          <description>Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="P5">
          <title>Natalizumab 150 mg IV Every 12 Weeks</title>
          <description>Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="P6">
          <title>Natalizumab 150 mg SC Every 12 Weeks</title>
          <description>Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="53">1 participant did not receive any study medication.</participants>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Rescue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Arm Closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Prior to Dosing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44">1 participant discontinued randomized period due to an adverse event but entered open-label period.</participants>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Period: Natalizumab 300 mg IV Every 4 Weeks</title>
          <description>Natalizumab 300 mg IV every 4 weeks for 60 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Randomized Period: Natalizumab 300 mg SC Every 4 Weeks</title>
          <description>Natalizumab 300 mg SC every 4 weeks for 60 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Randomized Period: Natalizumab 300 mg IV Every 12 Weeks</title>
          <description>Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="B4">
          <title>Randomized Period: Natalizumab 300 mg SC Every 12 Weeks</title>
          <description>Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="B5">
          <title>Randomized Period: Natalizumab 150 mg IV Every 12 Weeks</title>
          <description>Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="B6">
          <title>Randomized Period: Natalizumab 150 mg SC Every 12 Weeks</title>
          <description>Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="47"/>
            <count group_id="B6" value="38"/>
            <count group_id="B7" value="290"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="7.84"/>
                    <measurement group_id="B2" value="36.3" spread="8.92"/>
                    <measurement group_id="B3" value="38.7" spread="8.43"/>
                    <measurement group_id="B4" value="38.7" spread="7.85"/>
                    <measurement group_id="B5" value="38.7" spread="8.61"/>
                    <measurement group_id="B6" value="36.0" spread="9.03"/>
                    <measurement group_id="B7" value="37.9" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 56 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Number of Combined Unique Active Lesions</title>
        <description>Cumulative number of combined unique active lesions (sum of the number of new gadolinium (Gd)-enhancing lesions and new or newly enlarging T2 hyperintense lesions not associated with Gd-enhancement on T1 weighted scans) based on brain magnetic resonance imaging (MRI) scans Up to Week 60.</description>
        <time_frame>Up to Week 60</time_frame>
        <population>Modified intent-to-treat (mITT) population: all randomized participants who received at least 1 dose of study drug, had at least 1 efficacy assessment, and had no statistical protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Period: Natalizumab 300 mg IV Every 4 Weeks</title>
            <description>Natalizumab 300 mg IV every 4 weeks for 60 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Period: Natalizumab 300 mg SC Every 4 Weeks</title>
            <description>Natalizumab 300 mg SC every 4 weeks for 60 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Period: Natalizumab 300 mg IV Every 12 Weeks</title>
            <description>Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Period: Natalizumab 300 mg SC Every 12 Weeks</title>
            <description>Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods.</description>
          </group>
          <group group_id="O5">
            <title>Randomized Period: Natalizumab 150 mg IV Every 12 Weeks</title>
            <description>Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods.</description>
          </group>
          <group group_id="O6">
            <title>Randomized Period: Natalizumab 150 mg SC Every 12 Weeks</title>
            <description>Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Combined Unique Active Lesions</title>
          <description>Cumulative number of combined unique active lesions (sum of the number of new gadolinium (Gd)-enhancing lesions and new or newly enlarging T2 hyperintense lesions not associated with Gd-enhancement on T1 weighted scans) based on brain magnetic resonance imaging (MRI) scans Up to Week 60.</description>
          <population>Modified intent-to-treat (mITT) population: all randomized participants who received at least 1 dose of study drug, had at least 1 efficacy assessment, and had no statistical protocol deviations.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="1.262"/>
                    <measurement group_id="O2" value="0.02" spread="0.151"/>
                    <measurement group_id="O3" value="3.84" spread="8.054"/>
                    <measurement group_id="O4" value="3.08" spread="8.216"/>
                    <measurement group_id="O5" value="6.09" spread="15.424"/>
                    <measurement group_id="O6" value="6.44" spread="11.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were analyzed during the randomized and open-label (OL) periods separately. Randomized period: AEs, after 1st randomized dose on Day 0 and prior to OL infusion of natalizumab at Week 60 (±5 days); SAEs also between Screening and dosing on Day 0.</time_frame>
      <desc>OL period: on or after OL infusion of natalizumab at Week 60 through to Week 72 (±2 weeks). If participant did not receive natalizumab infusions during the OL period (Week 60 to Week 72), all events with an onset date after Day 0 were considered as occurring during the randomized treatment period. AE data is presented for the Safety Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Randomized Period: Natalizumab 300 mg IV Every 4 Weeks</title>
          <description>Natalizumab 300 mg IV every 4 weeks for 60 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Randomized Period: Natalizumab 300 mg SC Every 4 Weeks</title>
          <description>Natalizumab 300 mg SC every 4 weeks for 60 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Randomized Period: Natalizumab 300 mg IV Every 12 Weeks</title>
          <description>Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="E4">
          <title>Randomized Period: Natalizumab 300 mg SC Every 12 Weeks</title>
          <description>Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="E5">
          <title>Randomized Period: Natalizumab 150 mg IV Every 12 Weeks</title>
          <description>Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="E6">
          <title>Randomized Period: Natalizumab 150 mg SC Every 12 Weeks</title>
          <description>Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods.</description>
        </group>
        <group group_id="E7">
          <title>Open-label Period: Natalizumab 300 mg IV Every 4 Weeks</title>
          <description>Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="E8">
          <title>Open-label Period: Natalizumab 300 mg SC Every 4 Weeks</title>
          <description>Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="E9">
          <title>Open-label Period: Natalizumab 300 mg IV Every 12 Weeks</title>
          <description>Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="E10">
          <title>Open-label Period: Natalizumab 300 mg SC Every 12 Weeks</title>
          <description>Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="E11">
          <title>Open-label Period: Natalizumab 150 mg IV Every 12 Weeks</title>
          <description>Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
        <group group_id="E12">
          <title>Open-label Period: Natalizumab 150 mg SC Every 12 Weeks</title>
          <description>Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.0">Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Meningitis Enteroviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Progressive Multifocal Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nuclear Magnetic Resonance Imaging Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma In Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pathological Gambling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Automatic Bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.0">Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.0">Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nuclear Magnetic Resonance Imaging Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Study Medical Director</name_or_title>
      <organization>Biogen</organization>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

